Evotec SE today announced that the Company has been notified by its partner Bayer about the successful outcome of a combined Phase I/IIa study with the P2X3 antagonist BAY1817080, originating from the Evotec/Bayer multi-target alliance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-p2x3-antagonist-demonstrates-efficacy-against-refractory-chronic-cough-in-phase-ii-poc-5837